Abstract
Prostaglandin E1 (PgE1) treatment, known as Misoprostol, is used for 1st trimester missed abortion (MA) treatment, in a single dose or more when products of conception are not entirely expelled. However, an association between the use for multiple doses of Misoprostol and the occurrence of retained products of conception (RPOC) in the subsequent pregnancy, along with other adverse maternal outcome has not yet been evaluated. Our objective was to evaluate the effects of repeated Misoprostol doses on subsequent live pregnancy outcome, especially RPOC.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
